DUBLIN–(BUSINESS WIRE)–The “Pharmacy
Benefit Managers are under pressure: The industry is a lightning rod for
America’s healthcare system at its worst” report has been added
to ResearchAndMarkets.com’s offering.
Pharmacy Benefit Managers are under pressure: The industry is a
lightning rod for America’s healthcare system at its worst
Summary
By 2019, the Pharmacy Benefit Management market is forecast to grow to
$283bn. Acting as the middle men’ of America’s healthcare system, PBMs
process and coordinate the delivery of prescription drugs, and act as
intermediaries between payers and other value chain constituents. It is
one of the least regulated sectors of the health care system, lacking
transparency, choice, and ripe with conflicts of interest.
It is known that PBMs actively engage in conduct that harms the American
consumer. Yet, there is increasing pressure on the industry both from
healthcare buyers and politicians. A recent scandal surrounding the use
of gag clauses’ between PBMs and pharmacies has tapped into the deeply
rooted American believe in the free market, and made PBMs the scapegoat
of the ongoing political debate on high drug prices. The industry has
consolidated, and is set to defend itself against pressure on all sides,
including the entrance of a large corporate new entrant with an agenda
to reduce the skyrocketing prices of drugs in America’s healthcare
market.
Key Highlights
-
Pharmacy Benefit Management is a lucrative $283bn industry that has
outgrown its value. -
Pharmacy Benefit Management exploits informational asymmetries at the
heart of a complex healthcare system, lowering the quality and
increasing the cost of American healthcare. -
Pharmacy Benefit Management Industry is set to be shaken-up by the
entry of an Amazon/JP Morgan/Berkshire Hathaway joint venture. This
will change the structure of the industry.
Scope
- Examines the Pharmaceutical Benefit Management Industry
-
Evaluates future of Pharmaceutical Benefit Managers within America’s
healthcare - Assesses reasons behind the ballooning cost of America’s healthcare
- Looks at consolidation within the Pharmacy Benefit Management Industry.
Reasons to buy
- What is the future of American Healthcare?
- What is at the heart of healthcare inefficiency in the USA?
- How will the PBM industry evolve?
- How do PBMs make money?
- How will PBM consolidation affect patient healthcare?
Key Topics Covered:
- Overview
- Catalyst
- Summary
- PBMs: the tapeworm in American Healthcare
- Lucrative $283bn Pharmacy Benefit Management industry is hot topic
- 50% of the United States drug budget spent on specialty drugs
- Historically, PBMs were a countervailing power
- Expansion through the value chain towards the formulary
- Today, PBMs benefit from rebates, payments, and informational asymmetry
- Market opacity has led to rent-seeking by PBMs
- Drug rebates retained
- Algorithmic assistance
- Cream skimming
- Overpaying in confidence
- Your auditor, my auditor
- Attention is shifting to the ballooning costs’ of healthcare
- Amazon’s entry into the market intensifies consolidation
- Conclusions
- Appendix
- Sources
- Further Reading
- Ask the analyst
For more information about this report visit https://www.researchandmarkets.com/research/vq59wc/global_pharmacy?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Healthcare
Services, Drugstores
and Pharmacies